Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-01
2011-03-01
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021300
Reexamination Certificate
active
07897574
ABSTRACT:
The invention is concerned with the use of a peptide comprising the N-terminal sequenceGly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala- Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg (SEQ ID NO: 1)or any allelic variant or derivative of said peptide possessing the biological property of matching the inducible VE-cadherin binding motif on the Bβ-chain (i.e. Bβ15-42) of human fibrin for the preparation of a pharmaceutical preparation for the treatment of shock, more specifically of hemorrhagic shock.
REFERENCES:
patent: 5997844 (1999-12-01), Dean et al.
patent: 7271144 (2007-09-01), Petzelbauer et al.
patent: 414097 (2005-12-01), None
patent: 2544676 (2006-01-01), None
patent: WO-02/48180 (2002-06-01), None
patent: WO-2005/086578 (2005-09-01), None
patent: WO-2006/000007 (2006-01-01), None
Petzelbauer, P. et al., “The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury”,Nature Medicine, Nature Pubkishing Group, New York, NY, US, vol. 11, No. 3, Mar. 2005, pp. 298-304.
Ledgerwood, Anna M. et al. “A review of studies on the effects of hemorrhagic shock and resuscitation on the coagulation profile.”Journal of Trauma Injury Infection and Critical Care, vol. 54, No. 5 Supplement, Mar. 2003, pp. S68-S74.
Lee, M. E. et al. “Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages.”Molecules and Cells, Feb. 1999, vol. 9, No. 1, pp. 7-13.
Staton, C. A. et al. “The role of fibrinogen and related fragments in tumour angiogenesis and metastatis”Expert Opinion on Biologial Therapy, United Kingdom, 2003, vol. 3, No. 7, pp. 1105-1120.
Petzelbauer, P. et al., “The fibrin-derived peptide Bbetal5-42 protects the myocardium against ischemia-reperfusion injury”,Nature Medicine, Nature Pubkishing Group, New York, NY, US, vol. 11, No. 3, Mar. 2005, pp. 298-304.
Ledgerwood, Anna M. et al. “A review of studies on the effects of hemorrhagic shock and resuscitation on the coagulation profile.”Journal of Trauma Injury Infection and Critical Care, vol. 54, No. 5 Supplement, Mar. 2003, pp. S68-S74.
Lee, M. E. et al. “Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages.”Molecules and Cells, Feb. 1999, vol. 9, No. 1, pp. 7-13.
Staton, C. A. et al. “The role of fibrinogen and related fragments in tumour angiogenesis and metastatis”Expert Opinion on Biological Therapy, United Kingdom, 2003, vol. 3, No. 7, pp. 1105-1120.
Altieri, D. C., “Regulation of Leukocyte-Endothelium Interaction by Fibrinogen”, Thrombosis and Haemostasis, 1999, vol. 82, pp. 781-786.
Herrick, S. et al., Int. J. Biochem. Cell Biol., Jul. 1999, vol. 31, No. 7, pp. 741-746, Abstract.
Loike, John D. et al., “CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the Aœ chain of fibrinogen”, Proc. Natl. Acad. Sci., USA, Feb. 1991, vol. 88, pp. 1044-1048.
Van Gorp, Eric C. M. et al., “Impaired Fibrinolysis in the Pathogenesis of Dengue Hemorrhagic Fever”, Journal of Medical Virology, 2002, vol. 67, pp. 549-554.
Mairuhu et al., “Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence”, Lancet Infect. Dis., Jan. 2003, vol. 3, No. 1, pp. 33-41, Abstract.
Idell S., “Adult respiratory distress syndrome: do selective anticoagulants help?”, Am. J. Respir. Med., 2002, vol. 1, No. 6, pp. 383-391, Abstract.
Bach, et al., “VE-Cadherin mediates endothelial cell capillary tube formation in firbrin and collagen gels”, Exp. Cell Res., Feb. 1998, vol. 238, No. 2, pp. 324-334, Abstract.
Chalupowicz, Diana G. et al., “Fibrin II induces endothelial cell capillary tube formation”, The Journal of Cell Biology, Jul. 1995, vol. 130, No. 1, pp. 207-215.
Hamaguchi, M. et al., “Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta 15-42”, Blood, May 1, 1996, vol. 81, No. 9, pp. 2348-2356, Abstract.
Francis et al., “Endotheial cell responses to fibrin mediated by FPB cleavage and the amino terminus of the beta chain”, Blood Cells, 1993, vol. 19, No. 2, pp. 291-306, Abstract.
Sporn et al., “Cell proliferation on fibrin: modulation by fibrinopeptide cleavage”, Blood, Sep. 1, 1995, vol. 86, No. 5, pp. 1802-1810, Absract.
Ribes, Jule A. et al., “Fibrin induces release of von Willebrand factor from endothelial cells”, J. Clin. Invest., Jan. 1987, vol. 79, pp. 117-123.
Ribes, Julie A. et al., “Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin β chain”, J. Clin. Invest., Aug. 1989, vol. 84, pp. 435-442.
Erban et al., “A 130-kDa protein on endothelial cells binds to amino acids 15-42 of the B beta chain of fibrinogen”, J. Biol. Chem., Feb. 1992, vol. 267, No. 4, pp. 2451-2458, Abstract.
Harley, Suzanne L. et al., “Regulation by fibrinogen and its products of intercellular adhesion molecule-1 expression in human saphenous vein endothelial cells”, Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, vol. 20, pp. 650-658.
Bach, Tami J. et al., “Endothelial cell VE-cadherin function as a receptor for the β 15-42 sequence of fibrin”, J. Biol. Chem., Nov. 1998, vol. 273, No. 46, pp. 30719-30728.
Gorlatov, Sergei et al., “Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: Mapping of the receptor-binding site in the NH2-terminal portion sof the fibrin β chains”, Biochemistry, 2002, vol. 41, No. 12, pp. 4107-4116, Abstract.
Fareed et al., “Useful laboratory tests for studying thrombogenesis in acute cariac syndromes”, Clin. Chem., Aug. 1998, vol. 44, No. 8, pp. 1845-1853, Abstract.
Bruce et al., “Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain”, J. Clin Invest., vol. 89, pp. 842-850. (1992).
Qi et al., “Fibrin Regulation of Interleukin-8 Gene Expression in Human Vasular Endothelial Cells”, Blood, vol. 90, pp. 3593-3602, (1997).
Martinez et al. “Interaction of fibrin with VE-cadherin”, Ann NY Acad Sci., vol. 936, pp. 386-405, (2001).
Ikematsu, S. “Radioimmunoassy of fibronopeptide”, Rinsho kensa, 28, pp. 20-24, (1984), (CAS Abstract 100:188169).
Henning Rainer
Petzelbauer Peter
Bradley Christina
Hoffmann & Baron , LLP
Ikaria Development Subsidiary Two LLC
LandOfFree
Pharmaceutical composition for treating haemorrhagic shock... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for treating haemorrhagic shock..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for treating haemorrhagic shock... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2682591